Bank of New York Mellon Corp - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 126 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.9%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$247,308
+66.7%
133,6800.0%0.00%
Q4 2022$148,384
-56.2%
133,680
-7.6%
0.00%
Q3 2022$339,000
-11.5%
144,700
+14.5%
0.00%
Q2 2022$383,000
-55.7%
126,410
-0.7%
0.00%
Q1 2022$865,000
-18.5%
127,252
+0.2%
0.00%
Q4 2021$1,062,000
+11.6%
127,005
-0.8%
0.00%
Q3 2021$952,000
+37.0%
128,079
+25.2%
0.00%
Q2 2021$695,000
-4.9%
102,268
+43.7%
0.00%
Q1 2021$731,000
+45.0%
71,171
-1.2%
0.00%
Q4 2020$504,000
-66.8%
72,040
-61.3%
0.00%
Q3 2020$1,520,000
+9.7%
186,287
-7.2%
0.00%
Q2 2020$1,385,000
+39.5%
200,650
-4.0%
0.00%
Q1 2020$993,000
-48.3%
209,007
-5.1%
0.00%
Q4 2019$1,922,000
+576.8%
220,131
+158.5%
0.00%
Q3 2019$284,000
-32.5%
85,166
+0.2%
0.00%
Q2 2019$421,000
+0.2%
85,021
+25.4%
0.00%
Q1 2019$420,000
+80.3%
67,803
-1.8%
0.00%
Q4 2018$233,000
-24.6%
69,068
+45.1%
0.00%
Q3 2018$309,000
-15.3%
47,593
+0.1%
0.00%
Q2 2018$365,000
-66.4%
47,568
-2.2%
0.00%
Q1 2018$1,087,000
+85.8%
48,640
+6.0%
0.00%
Q4 2017$585,000
-9.4%
45,889
+10.8%
0.00%
Q3 2017$646,000
+79.9%
41,422
+62.0%
0.00%
Q2 2017$359,000
-6.8%
25,574
+46.0%
0.00%
Q1 2017$385,00017,5110.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
TRV GP II, LLC 9,200,349$64,402,00044.86%
TRV GP III, LLC 3,048,780$21,342,0001.83%
SILVERARC CAPITAL MANAGEMENT, LLC 406,665$2,847,0001.65%
Sofinnova Investments, Inc. 925,280$6,477,0000.39%
Omega Fund Management, LLC 334,965$2,345,0000.35%
Yorktown Management & Research Co Inc 49,200$344,0000.31%
Woodline Partners LP 940,902$6,586,0000.18%
HUSSMAN STRATEGIC ADVISORS, INC. 51,000$357,0000.09%
HORIZON FINANCIAL SERVICES, LLC 12,005$84,0000.08%
Gyon Technologies Capital Management, LP 26,893$188,0000.06%
View complete list of JOUNCE THERAPEUTICS INC shareholders